56 m a s s a g e & b o d y w o r k s e p t e m b e r / o c t o b e r 2 0 1 9
12. Anna Maria Malfitano, Maria Chiara Proto, and
Maurizio Bifulco, "Cannabinoids in the Management
of Spasticity Associated with Multiple Sclerosis,"
Neuropsychiatric Disease and Treatment 4, no. 5
(October 2008): 847–53; C. Collin et al., "A Double-
Blind, Randomized, Placebo-Controlled, Parallel-
Group Study of Sativex, in Subjects with Symptoms
of Spasticity Due to Multiple Sclerosis," Neurological
Research 32, no. 5 (June 2010): 451–9, https://
doi.org/10.1179/016164109X12590518685660.
13. Dementia Care Central, "CBD: A Natural Remedy
that Decreases Symptomatic Behaviors of Parkinson's
Disease?" last updated February 26, 2019, accessed
August 2019, www.dementiacarecentral.com/
parkinsons/treating/cbd; Fernanda F. Peres et al.,
"Cannabidiol as Promising Strategy to Treat and Prevent
Movement Disorders?" Frontiers in Pharmacology 9
(2018): 482, https://doi.org/10.3389/fphar.2018.00482.
14. Carlos A. Salgado and Daniel Castellanos,
"Autism Spectrum Disorder and Cannabidiol: Have
We Seen This Movie Before?" Global Pediatric
Health 5 (2018): 2333794X18815412, https://doi.
org/10.1177/2333794X18815412; Tricia Romano,
"Part 1, Autism and Cannabis: Here's What the
Science Says," Leafly, June 20, 2018, accessed
August 2019, www.leafly.com/news/health/autism-
and-cannabis-heres-what-the-science-says.
15. M. M. Bergamaschi et al., "Safety and Side Effects of
Cannabidiol, a Cannabis Sativa Constituent," Current
Drug Safety 6, no. 4 (September 2011): 237–49.
16. Timothy E. Welty, Adrienne Luebke, and Barry E.
Gidal, "Cannabidiol: Promise and Pitfalls," Epilepsy
Currents 14, no. 5 (September-October 2014): 250–2,
https://doi.org/10.5698/1535-7597-14.5.250.
17. World Anti-Doping Agency, "Prohibited In-
Competition," accessed August 2019, www.wada-ama.
org/en/content/what-is-prohibited/prohibited-in-
competition/cannabinoids; World Health Organization,
Cannabidiol (CBD) Pre-Review Report, November
2017, accessed August 2019, www.who.int/medicines/
access/controlled-substances/5.2_CBD.pdf.
Julie Crispin has been a licensed massage
therapist in Oregon since 2007. She has a
thriving private practice and teaches CE classes
nationally on the subject of CBD and massage.
She has served in several volunteer positions in
the massage profession and is currently on the
Oregon Board Massage Therapists Education
Advisory Committee. For more information about
her work, visit www.massagetopicals.com.
Karrie Osborn is senior editor at Associated
Bodywork & Massage Professionals.
Photo
by
Casey
Hogan
A Guide to Incorporating CBD Into Your Practice
• Do your research and educate yourself and your clients about CBD.
• Find the product that is right for you and your clients. There may be more
than one product that works for different situations.
• Confirm whether a product is transdermal. If it is, decide whether you should
use gloves. If a product is transdermal—and full spectrum—there is the
chance that some THC could show up in a drug test.
• Keep your marketing language rooted in science-based evidence and don't
make unsubstantiated health claims.
• Check your state and local regulations regarding the use of CBD in your
practice and/or your ability to sell CBD products.
• If CBD is named in your billing or booking services, it's important to check
with your bank and your vendors to ensure you won't lose their services by
providing CBD in your business. Local credit unions are good alternatives.
• Confirm that your liability insurance covers you for using CBD.
• Obtain written consent from your client if you choose to use CBD. (Find a
sample CBD waiver in this issue's digital edition.)
• Find your price. Some add CBD to massage for a $10 upcharge, while some
spas charge up to $200 for a CBD spa service.
